Gainers
- Reshape Lifesciences RSLS stock rose 30.2% to $0.27 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 104.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.
- Cognition Therapeutics CGTX shares rose 11.57% to $1.35. The market value of their outstanding shares is at $40.9 million.
- GRI Bio GRI shares increased by 10.08% to $1.2. The company's market cap stands at $3.5 million.
- Vicarious Surgical RBOT shares moved upwards by 10.06% to $0.41. The company's market cap stands at $70.6 million.
- AcelRx Pharmaceuticals ACRX shares increased by 9.8% to $0.56. The market value of their outstanding shares is at $9.1 million.
- AlloVir ALVR shares increased by 9.15% to $1.55. The company's market cap stands at $176.4 million.
Losers
- Tharimmune THAR shares declined by 20.6% to $0.2 during Tuesday's after-market session. This security traded at a volume of 559.5K shares come close, making up 35.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.5 million.
- Biocept BIOC shares declined by 17.27% to $0.36. Today's trading volume for this security ended up closing at 129.0K shares, which is 6.1 percent of its average volume over the last 100 days.
- Sonnet BioTherapeutics SONN shares fell 13.26% to $1.57. The market value of their outstanding shares is at $2.7 million.
- Motus GI Hldgs MOTS shares fell 11.37% to $0.59. Motus GI Hldgs's trading volume hit 1.6 million shares by close, accounting for 1949.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.4 million.
- IO Biotech IOBT stock decreased by 9.35% to $0.97. The company's market cap stands at $63.9 million.
- Titan Pharma TTNP shares fell 9.16% to $0.35. The company's market cap stands at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in